Information has been received from a healthcare worker for VARIVAX (Merck), a Pregnancy Registry product, concerning a 17 year old female patient with no allergies or drug reactions and no pertinent medical history who on 01-OCT-1996 was vaccinated with the first dose of VARIVAX (Merck) (Dose, route, lot # and expiration not reported) and on 24-AUG-2011 received the second dose of VARIVAX (Merck) (Dose, route and lot # and expiration not reported). Concomitant therapy included MENACTRA and HAVRIX. It was reported that on 24-AUG-2011 the patient was vaccinated with the second dose of VARIVAX (Merck) and was pregnant, a pregnancy test and lab work were performed and were positive (LMP and EDD were unspecified). No adverse effects were reported.  Follow up information was received for initial pregnancy questionnaire from a physician concerning a female patient with 1 previous pregnancy (without any birth defect or miscarriage) who was not tested for varicella antibodies before vaccination with VZV containing vaccine, who on 24-AUG-2011 was vaccinated with the second dose of VARIVAX (Merck) (lot # E008907). On 04-OCT-2011, routine labs were performed: ultrasound done (results not provided) (labs not back at the time). It was reported that the patient did not experience any local reaction at the vaccination site or any varicella or herpes Zoster symptoms post vaccination. Follow up information has been received from a nurse who reported that the patient gave birth to a healthy baby boy on 08-FEb-2012 at 39/2 weeks gestation. The patient's LMP was on 13-MAY-2011 and EDD was on 13-FEB-2012. The pregnancy and vaginal delivery was without complications. The baby had no congenital anomalies. Follow up information was received from a licensed practical nurse via a pregnancy questionnaire indicated that the female patient with 2 previous pregnancies, 2 full term deliveries was vaccinated with a first dose of VARIVAX (Merck) (Dose, route, lot # and expiration not reported) and on 24-AUG2-2011 received the second dose of VARIVAX (Merck) (Dose, route and lot # and expiration not reported) (vaccine booster). Concomitant medications included MENACTRA and HAVRIX. On 13-OCT-2011 an ultrasound for screening was made and the results showed Right Pyelectasis and the patient was referred to prenatal specialist. On 20-FEB-2012 the patient experienced nausea and was treated with ZOFRAN and on 19-DEC-2011 the patient experienced anemia and was treated with ferrous sulfate. It was reported that the patient was not tested for varicella antibodies before vaccination with VZV containing vaccine. The licensed practical nurse stated that the patient not experienced local reaction at the vaccination site or presented varicella or herpes zoster symptoms post vaccination. On 08-FEB-2012, at 39 weeks since last menstrual period the patient delivered a normal baby who weighted 8 pounds 11 oz with no complications or abnormalities. There were no congenital anomalies reported. On an unspecified date a level II ultrasound was performed for dilated uthers (no results provided). At the time of reporting, the patient's outcome from right pyelectasis, nausea and anemia were unknown. Additional information is not expected.